Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Bioconjugate Chemistry

Rapid and Efficient Antibody–Drug Conjugate Design Using Mechanistic Bottom-Up Modeling from In Vitro to Human

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJan-Philip KahlJSJudith SteinTLTatu Lindroos

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates effective design of antibody-drug conjugates in humans, suggesting improvements for clinical success.

Key Points

  • The study aims to develop a predictive modeling strategy for antibody-drug conjugates (ADCs) to improve clinical trial success.
  • Developed a bottom-up mechanistic modeling strategy to predict ADC efficacy and toxicity.
  • Validated the model with six different ADCs (Enhertu, Kadcyla, Trodelvy, RC48, RN927C, Datroway).
  • Utilized pharmacokinetic and pharmacodynamic parameters to forecast in vitro and in vivo efficacy.
  • Achieved 94.64% accuracy in predicting ADC in vitro potency within a 2-fold range.
  • Predicted in vivo efficacy trends matching literature data for cell line- and patient-derived xenografts.
  • Successfully forecasted hematologic toxicities, including neutropenia and thrombocytopenia for Kadcyla and Enhertu.

Cite This Study

Kahl et al. (2026) studied this question.

synapsesocial.com/papers/6a363274db0793dc1a53901ehttps://doi.org/10.1021/acs.bioconjchem.6c00049
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Applications of Pharmacometrics in Antibody–Drug Conjugate Development2026 · 2 citations
  2. 2Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies2025
  3. 3Abstract 1706: An integrate comprehensive <i>in vitro</i> and <i>in vivo</i> strategies for antibody drug conjugate development2026
  4. 4PBPK-PD Model for Predicting Pharmacokinetics, Tumor Growth Inhibition, and Toxicity Risks of Topoisomerase Inhibitor ADCs in Mice and Humans2025 · 5 citations
  5. 5Abstract 4398: Developing 3D cell models for high-throughput antibody-drug conjugate screening in cancer2026